[1] Yoshii T, Magara S, Miyai D, et al. Local Levels of Interleukin-1β, -4, -6, and Tumor Necrosis Factor α in an Experimental Model of Murine Osteomyelitis Due to Staphylococcus Aureus [J]. Cytokine, 2002, 19(2)∶59-65 [2] Scianaro R, Insalaco A, Bracci L, et al. Deregulation of the IL-1β axis in chronic recurrent multifocal osteomyelitis [J]. Pediatric Rheumatology, 2014,12(1)∶30-35 [3] Evans C, Jellis J, Hughes S, et al. Tumor necrosis factor-α, interleukin-6, and interleukin-8 secretion and the acute-phase response in patients with bacterial and tuberculous osteomyelitis [J]. Journal of Infectious Diseases, 1998,177(6)∶1582-1587 [4] Hofmann S, Kubasch AS, Range U, et al. Serum biomarkers for the diagnosis of chronic recurrent multifocal osteomyelitis (CRMO) [J]. Pediatric Rheumatology, 2015, 13(Suppl 1)∶O77 [5] Van Asten SA, Nichols A, La Fontaine J, Bhavan K, Peters EJ, Lavery LA. The value of inflammatory markers to diagnose and monitor diabetic foot osteomyelitis [J]. Int Wound J, 2017, 14(1)∶40-45 [6] Fullilove S, Jellis J, Hughes S, et al. Local and systemic concentrations of tumour necrosis factor-α, interleukin-6 and interleukin-8 in bacterial osteomyelitis [J]. Transactions of the Royal Society of Tropical Medicine & Hygiene, 2000, 94(2)∶221-224 [7] Jin W, Dong C. IL-17 cytokines in immunity and inflammation [J]. Emerg Microbes Infect, 2013, 2(9)∶e60 [8] Ruscitti P, Cipriani P, Carubbi F, et al. The role of IL-1beta in the bone loss during rheumatic diseases [J]. Mediators Inflamm, 2015, 2015∶1-10 [9] 余科,吴湘楠,刘文佳,等.LPS刺激小鼠骨细胞RANKL/OPG和IL-6表达的实验研究[J].口腔医学研究,2016,32(3)∶220-223 [10] Kim YG, Park JW, Lee JM, et al. IL-17 inhibits osteoblast differentiation and bone regeneration in rat [J]. Archives of Oral Biology, 2014, 59(9)∶897-905 [11] Croes M, ner FC, van Neerven D, et al. Proinflammatory T cells and IL-17 stimulate osteoblast differentiation [J]. Bone, 2016, 84(2)∶262-270 [12] Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic intervention [J]. Dressnature Reviews Drug Discovery, 2012, 11(3)∶234-250 [13] Souza PP, Lerner UH. The role of cytokines in inflammatory bone loss [J]. Immunol Invest, 2013, 42(7)∶555-622 [14] Hughes FJ, Turner W, Belibasakis G, et al. Effects of growth factors and cytokines on osteoblast differentiation [J]. Periodontology, 2006, 41(1)∶48-72 [15] Shaw AT, Gravallese EM. Mediators of inflammation and bone remodeling in rheumatic disease [J]. Semin Cell Dev Biol, 2016, 49(1)∶2-10 [16] 朱建华,杨艳飞,李晓光,刘继光. α通过血清中TNF-α、IL-17、IL-23的水平研究慢性牙周炎和类风湿性关节炎的相关性[J].口腔医学研究,2015,31(12)∶1220-1222+1227 [17] Hofmann SR, Kubasch AS, Range U, et al. Serum biomarkers for the diagnosis and monitoring of chronic recurrent multifocal osteomyelitis (CRMO) [J]. Rheumatology International, 2016, 36(6)∶1-11 [18] Espirito Santo AI, Ersek A, Freidin A, et al. Selective inhibition of TNFR1 reduces osteoclast numbers and is differentiated from anti-TNF in a LPS-driven model of inflammatory bone loss [J]. Biochemical & Biophysical Research Communications, 2015, 464(4)∶1145 [19] Murakami M, Nishimoto N. IL-6 inhibitors prevent bone loss and cartilage degeneration in rheumatoid arthritis [J]. Clinical Calcium, 2015, 25(12)∶1851-1857 [20] Kunwar S, Dahal K, Sharma S. Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials [J]. Rheumatol Int, 2016, 36(8)∶1-11 [21] Lukens JR, Gross JM, Calabrese C, et al. Critical role for inflammasome-independent IL-1β production in osteomyelitis [J]. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111(3)∶1066-1071 [22] 崔莹,吕达,乔文波.IL -6、IL -8和 IL -10与放射性肺损伤相关性研究[J].实用肿瘤学杂志,2014,3∶202-206 |